Publications

Add filters (0)

6 results

Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.

February 1, 2021

J Viral Hepat

Abstract The effect of direct-acting antiviral (DAA) therapy on extracellular matrix (ECM) turnover, a prominent feature of chronic hepatitis C (CHC), is unknown. ECM protein degradation and formation generate fragments reflecting the tissue turnover balance when quantified in the blood. PRO-C3 and PRO-C4 reflect type III and IV collagen formation; C3M and C4M are degradation […]

Read publication

PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C.

January 1, 2018

Scand J Gastroenterol

Abstract OBJECTIVE Detecting significant fibrosis and cirrhosis remains important in treatment and follow-up of patients with chronic hepatitis C Infection (CHC). The aim of this study was to assess the ability of PRO-C3 to identify significant fibrosis (Ishak score ≥3) and cirrhosis (Ishak score ≥5) both as a single test and as a part of algorithms. MATERIALS […]

Read publication

Fibrosis is not just fibrosis – basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury.

December 1, 2016

Aliment Pharmacol Ther

Abstract BACKGROUND While morphological patterns differ, the molecular phenotype of liver fibrosis is considered a stereotypical response to chronic liver injury. However, with different cellular triggers and networks regulating fibrosis, the molecular responses of the injured liver may not be identical. AIM To investigate whether differences in extracellular matrix (ECM) composition of the liver during […]

Read publication

Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C.

February 1, 2015

Liver Int

Abstract BACKGROUND & AIMS Fibrogenesis results in release of certain extracellular matrix protein fragments into the circulation. We evaluated the diagnostic and prognostic performance of two novel serological markers, the precisely cleaved N-terminal propeptide of type III collagen (Pro-C3) and a peptide of helical collagen type III degradation (C3M), in chronic hepatitis C (CHC) patients. […]

Read publication

Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients.

January 1, 2015

PLoS One

Abstract BACKGROUND AND AIM Detection of advanced fibrosis (Metavir F≥3) is important to identify patients with a high urgency of antiviral treatments vs. those whose treatment could be deferred (F≤2). The aim was to assess the diagnostic value of novel serological extracellular matrix protein fragments as potential biomarkers for clinically significant and advanced fibrosis. METHODS […]

Read publication

PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertension.

January 1, 2014

PLoS One

Abstract BACKGROUND Liver-related deaths represent the leading cause of mortality among patients with HIV/HCV-co-infection, and are mainly related to complications of fibrosis and portal hypertension. In this study, we aimed to evaluate the structural changes by the assessment of extracellular matrix (ECM) derived degradation fragments in peripheral blood as biomarkers for fibrosis and portal hypertension […]

Read publication